PHILADELPHIA (May 24, 2021)—Mary B. Daly, MD, PhD, FACP, professor in the Department of Clinical Genetics and director of the Risk Assessment Program at Fox Chase Cancer Center, recently received the National Comprehensive Cancer Network’s (NCCN) Rodger Winn Award.

PHILADELPHIA (May 18, 2021)—Data from a new study by researchers at Fox Chase Cancer show that avapritinib, a platelet-derived growth factor receptor A (PDGFRA) inhibitor, has a “clinically meaningful benefit” for the treatment of gastrointestinal stromal tumors (GIST) with PDGFRA D842V mutations.

PHILADELPHIA (May 14, 2021)—In early 2020, Sanjay S. Reddy, MD, FACS, surgical oncologist and co-director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center, co-authored an article examining the paradox that healthcare providers were facing. Should they continue to treat cancer patients as they normally would, which might increase the risk of contracting COVID-19? Or should they try alternative strategies to treatment, which could lead to worse cancer-related outcomes?